news.theglobaltribune.comThe Global Tribune

Pancreatic Cancer Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight | Keymed Biosciences Co, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics The Pancreatic Cancer Market size was valued approximately USD 1,700 million in 2022 and the report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the 7MM. The Pancreatic Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics. DelveInsight’s Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Pancreatic Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pancreatic Cancer Market Forecast Some of the key facts of the Pancreatic Cancer Market Report: The Pancreatic Cancer market size was valued approximately USD 1,700 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In January 2024, Amplia Therapeutics disclosed that the US FDA has approved Amplia’s Investigational New Drug (IND) application for conducting a trial involving narmafotinib, Amplia’s leading focal adhesion kinase (FAK) inhibitor, in pancreatic cancer. In January 2023, Alligator Bioscience disclosed promising interim results from the ongoing OPTIMIZE-1 Phase 2 trial of their primary asset, mitazalimab, in first-line metastatic pancreatic cancer. This open-label, multi-center study assesses the safety and effectiveness of mitazalimab (CD40 mAb) combined with the chemotherapy medication mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma who have not undergone prior treatment. The 2023 analysis indicates that in the EU4 and the UK, the number of incident cases of pancreatic cancer varied by stage, with the highest number observed in the distant stage at approximately 38,000 cases, followed by regional and localized stages at around 28,000 and 8,600 cases, respectively. The overall number of new cases of pancreatic cancer in the seven major markets (7MM) was approximately 180,000 in 2022, with an anticipated rise projected throughout the forecast period. In 2022, Germany registered the greatest number of cases, making up around 30% of cases in both the EU4 and the UK. Conversely, Spain recorded the fewest number of cases in the EU4 and the UK region. In 2022, approximately 12,400 new cases of pancreatic cancer were reported in the UK. It is anticipated that these numbers will rise by 2032. The 2022 analysis indicates that in the EU4 and the UK, the highest number of stage-specific incident cases of pancreatic cancer occurred in the distant stage, totaling around 37,000 cases. This was followed by regional and localized stages, with approximately 28,000 and 8,400 cases, respectively. Key Pancreatic Cancer Companies: Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others Key Pancreatic Cancer Therapies: DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others The Pancreatic Cancer epidemiology based on gender analyzed that males are more commonly affected in case of Pancreatic Cancer than females Request a sample for the Pancreatic Cancer Market Report: https://www.delveinsight.com/report-store/pancreatic-cancer-market Pancreatic Cancer Overview Pancreatic adenocarcinoma is one of the most aggressive forms of cancer and is projected to arise as the second leading cause of cancer-related deaths in Europe and the United States in the near future. In the US, pancreatic cancer is the 9th or 10th most commonly diagnosed cancer (depending on gender). A clinical/radiographic stage classification for pancreatic cancer suggests three stage classification(potentially resectable, locally advanced, and advanced) of pancreatic cancer involvement based on radiological findings. Pancreatic Cancer Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The Pancreatic Cancer epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Pancreatic Cancer Epidemiology Segmentation: The Pancreatic Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Pancreatic Cancer Prevalent Cases of Pancreatic Cancer by severity Gender-specific Prevalence of Pancreatic Cancer Diagnosed Cases of Episodic and Chronic Pancreatic Cancer Download the report to understand which factors are driving Pancreatic Cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights Pancreatic Cancer Market The dynamics of the Pancreatic Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Niraparib, Dostarlimab, and others during the forecasted period 2020-2034. Pancreatic Cancer Therapies and Key Companies DF 7001: Dragonfly Therapeutics CMG 901 Keymed B TNG260: Tango Therapeutics ATA 3271: Atara Biotherapeutics CMG 901: Keymed Biosciences Co.Ltd CT-0508: Carisma Therapeutics Inc CUE-102: Cue Biopharma BOLD-100: Bold Therapeutics CM24: Purple Biotech Ltd ENB-003: ENB Therapeutics GRT-C903: Gritstone bio AZD0171: AstraZeneca CAN-2409: Candel Therapeutics Mitazalimab: Alligator Bioscience Pamrevlumab: FibroGen NIS793: Novartis AG Masitinib: AB Science Glufosfamide: Eleison Pharmaceuticals To know more about Pancreatic Cancer treatment, visit @ Pancreatic Cancer Medications Pancreatic Cancer Market Strengths Rising cases of pancreatic cancer results in increasing market size. Biomarkers play an important role in the clinical management of pancreatic cancer patients with the emergence of genomic profiling technologies and selective molecular targeted therapies. Survival is steadily improving, emphasizing that a deeper understanding of tumor pathology will lead to improved therapies and outcomes in pancreatic cancer patients. Pancreatic Cancer Market Opportunities An investigation into the use of newer and more active systemic regimens in the neoadjuvant setting to treat PDAC could potentially improve outcomes as there is a lack of randomized neoadjuvant trials. Agents targeting KRAS, TP53, CDKN2A, and SMAD4, the four common mutations in pancreatic cancer, are still under clinical investigation. Scope of the Pancreatic Cancer Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Pancreatic Cancer Companies: Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others Key Pancreatic Cancer Therapies: DF 7001, TNG260, ATA 3271, CMG 901,...